{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:23:13Z","timestamp":1776201793392,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1136\/ard.2004.034157","type":"journal-article","created":{"date-parts":[[2005,2,11]],"date-time":"2005-02-11T18:28:43Z","timestamp":1108146523000},"page":"ii78-ii82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"S2","title":["Psoriatic arthritis treatment: biological response modifiers"],"prefix":"10.1016","volume":"64","author":[{"given":"P J","family":"Mease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C E","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2004.034157_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1297-319X(02)00363-9","article-title":"The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis","volume":"69","author":"Dayer","year":"2002","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard.2004.034157_bib2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.034157_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2004.034157_bib4","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib5","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2004.034157_bib6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.034157_bib7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.034157_bib8","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"suppl II","key":"10.1136\/ard.2004.034157_bib9","doi-asserted-by":"crossref","first-page":"ii40","DOI":"10.1136\/ard.2004.031559","article-title":"Immunology, cellular pathology, genetics","volume":"64","author":"Ritchlin","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.034157_bib10","first-page":"S266","article-title":"Infliximab reduces the expression of adhesion molecules in skin and synovial tissue of patients with psoriatic arthritis","volume":"48","author":"Tak","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2004.020719","article-title":"TNF alpha therapy in psoriatic arthritis and psoriasis","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.034157_bib12","series-title":"Enbrel\u00ae (Etanercept) prescribing information","year":"2003"},{"key":"10.1136\/ard.2004.034157_bib13","first-page":"S391","article-title":"Randomized controlled trial of 25 mg vs. 59 mg dose Enbrel (etanercept) twice weekly in rheumatoid arthritis (RA)","volume":"43","author":"Schiff","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"suppl II","key":"10.1136\/ard.2004.034157_bib15","doi-asserted-by":"crossref","first-page":"ii49","DOI":"10.1136\/ard.2004.034165","article-title":"Psoriatic arthritis assessment tools in clinical trials","volume":"64","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"suppl 1","key":"10.1136\/ard.2004.034157_bib16","first-page":"146","article-title":"Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis","volume":"60","author":"Mease","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.034157_bib17","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"suppl 1","key":"10.1136\/ard.2004.034157_bib18","first-page":"391","article-title":"How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) group guidelines","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"suppl 1","key":"10.1136\/ard.2004.034157_bib19","first-page":"99","article-title":"Etanercept in psoriatic arthritis: sustained improvement in joint and skin disease and inhibition of radiographic progression at 2 years","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.034157_bib20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.10671","article-title":"Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation","volume":"47","author":"Antoni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.61.3.207","article-title":"Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up","volume":"61","author":"Kruithof","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.034157_bib22","article-title":"The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib23","first-page":"S265","article-title":"The one year results of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy","volume":"48","author":"Antoni","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"suppl 1","key":"10.1136\/ard.2004.034157_bib24","first-page":"402","article-title":"Infliximab improves arthritis and psoriasis in patients with active polyarticular psoriatic arthritis: results of the IMPACT II trial","volume":"63","author":"Kavanaugh","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.034157_bib25","first-page":"S616","article-title":"Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from IMPACT 2 trial","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib26","first-page":"S450","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year","volume":"50","author":"Antoni","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"suppl 1","key":"10.1136\/ard.2004.034157_bib27","first-page":"403","article-title":"Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis","volume":"63","author":"Ritchlin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.034157_bib28","article-title":"Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib29","first-page":"1369","article-title":"Onercept. Serono","volume":"4","author":"Nikas","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1136\/ard.2004.034157_bib30","first-page":"S538","article-title":"The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis","volume":"46","author":"Hansen","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"suppl 1","key":"10.1136\/ard.2004.034157_bib31","first-page":"178","article-title":"The Canadian biologic observational switchover survey (BOSS): switching from infliximab to etanercept leads to successful treatment of rheumatoid arthritis","volume":"62","author":"Haraoui","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.034157_bib32","first-page":"S187","article-title":"Efficacy evaluation of adalimumab (Humira\u00ae) in patients with single and multiple prior biologics in the ReAct trial","volume":"50","author":"Bombardieri","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1172\/JCI200316069","article-title":"Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2004.034157_bib34","first-page":"S168","article-title":"Early effects of infliximab therapy on inflammatory cells in lesional epidermis and synovial tissue if patients with psoriatic arthritis","volume":"48","author":"Tak","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib35","first-page":"S266","article-title":"Infliximab reduces the expression of adhesion molecules in skin and synovial tissue of patients with psoriatic arthritis","volume":"48","author":"Tak","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib36","first-page":"S168","article-title":"Anti-TNF alpha therapy in psoriasis and psoriatic arthritis: clinical and angiogenic responses","volume":"48","author":"Veale","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib37","series-title":"Rheumatology Educational Initiative (REDI): Making a Difference in Rheumatology","first-page":"137","article-title":"RA therapy with biologics: safety and long-term considerations","author":"Cohen","year":"2004"},{"key":"10.1136\/ard.2004.034157_bib38","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000069965","article-title":"Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy","volume":"206","author":"Devos","year":"2003","journal-title":"Dermatology"},{"key":"10.1136\/ard.2004.034157_bib39","series-title":"Humira\u2122. (adalimumab) prescribing information","year":"2003"},{"key":"10.1136\/ard.2004.034157_bib40","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/ard.2004.034157_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.immunol.19.1.93","article-title":"Immunology of tuberculosis","volume":"19","author":"Flynn","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/ard.2004.034157_bib42","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","article-title":"Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology","volume":"69","author":"Mohan","year":"2001","journal-title":"Infect Immun"},{"issue":"suppl 9","key":"10.1136\/ard.2004.034157_bib43","first-page":"S241","article-title":"Granulomatous infections and tumor necrosis factor antagonist therapies: update through June","volume":"48","author":"Ruderman","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"suppl 2","key":"10.1136\/ard.2004.034157_bib44","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/ard.2004.029272","article-title":"Updated consensus statement on biological agents, specifically tumor necrosis factor \u03b1 (TNF\u03b1) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004","volume":"63","author":"Furst","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.034157_bib45","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1136\/ard.2004.034157_bib47","first-page":"98","article-title":"Lymphoma risk in ankylosing spondylitis patients is greater than that observed in the general population","volume":"63","author":"Shibata","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.034157_bib48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0049-0172(99)80026-2","article-title":"The incidence of cancer associated with the treatment of rheumatoid arthritis","volume":"29","author":"Beauparlant","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib49","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib50","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib51","first-page":"S81","article-title":"Long-term follow-up of patients treated with remicade (infliximab) in clinical trials","volume":"44","author":"Kavanaugh","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib52","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-137-7-200210010-00030","article-title":"Infliximab-induced systemic lupus erythematosus","volume":"137","author":"Ali","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2004.034157_bib53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","article-title":"Anti-TNF-alpha-induced systemic lupus syndrome","volume":"22","author":"Debandt","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2004.034157_bib54","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00054725-200305000-00005","article-title":"A lupus-like syndrome associated with infliximab therapy","volume":"9","author":"Klapman","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/ard.2004.034157_bib55","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard.2004.034157_bib56","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.034157_bib57","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1136\/ard.2004.034157_bib58","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1136\/ard.2004.034157_bib59","series-title":"Remicade\u00ae. (infliximab) prescribing information","year":"2003"},{"key":"10.1136\/ard.2004.034157_bib60","series-title":"Rheumatology Educational Initiative (REDI): Making a Difference in Rheumatology","first-page":"231","article-title":"The pathogenesis and treatment of psoriasis","author":"Menter","year":"2004"},{"key":"10.1136\/ard.2004.034157_bib61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","article-title":"An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis","volume":"139","author":"Lebwohl","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2004.034157_bib62","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1002\/art.10543","article-title":"Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis","volume":"46","author":"Kraan","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.034157_bib63","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","article-title":"A novel targeted T-cell modulator, efalizumab, for plaque psoriasis","volume":"349","author":"Lebwohl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.034157_bib64","unstructured":"Mease P. Efalizumab in psoriatic arthritis. Presentation at International Psoriasis Society, Toronto :2004."},{"key":"10.1136\/ard.2004.034157_bib65","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","article-title":"CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris","volume":"103","author":"Abrams","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2004.034157_bib66","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.034157_bib67","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.coph.2004.04.003","article-title":"Interleukin-15: a new cytokine target for the treatment of inflammatory diseases","volume":"4","author":"McInnes","year":"2004","journal-title":"Curr Opin Pharmacol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724424205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724424205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2004.034157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T05:15:11Z","timestamp":1737263711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724424205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":66,"alternative-id":["S0003496724424205"],"URL":"https:\/\/doi.org\/10.1136\/ard.2004.034157","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriatic arthritis treatment: biological response modifiers","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2004.034157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}